and as Potential Signatures for Glioma Recurrence, Regardless of WHO Tumor Grade.

Background/aim: Micro RNAs (miRs; miRNAs) are small, non-coding RNA segments that influence gene expression. To do this, they bind to corresponding mRNA segments and inhibit the subsequent protein translation. Currently, about 200 transcripts are thought to be regulated by a single miRNA.

Higher YAP1 Levels Are Associated With Shorter Survival of Patients With Low Grade Astrocytoma.

Background/aim: Glioblastoma multiforme (GBM) is one of the most lethal types of brain cancer with a median survival of only 12 months due to its aggressiveness and lack of effective treatment options. Astrocytomas and oligodendrogliomas are classified as low-grade gliomas (LGG) and have the potential to progress into secondary GBM. YAP1 and TAZ are transcriptional co-activators of the hippo pathway and play an important role in tumorigenesis by controlling cell proliferation and differentiation.

Expression of Is Up-regulated in Low-grade Glioma and Positively Correlated With Meningioma Grade.

Background: α-Enolase (ENO1) is a glycolytic enzyme involved in the Warburg effect which cancer cells utilize to satisfy their higher need for nutrients. Up-regulation of ENO1 has been detected in several tumor types, including melanoma and endometrial, gastric and colorectal cancer. In these tumors, ENO1 may function as prognostic marker.

Death Receptor 6 as a Prognostic Marker in Low-grade Glioma.

Background/aim: Low-grade gliomas (LGG) are heterogenous tumours, causing variable survivals in patients. Identifying molecular markers for a more accurate prognosis is, therefore, important. Since death receptor 6 (DR6) is up-regulated in gliomas and shows an aberrant signalling network, we tested its suitability as a prognostic marker.

TERT and its binding protein: overexpression of GABPA/B in high grade gliomas.

Enhanced expression of TERT in gliomas is a result of two hotspot mutations, C228T and C250T, at the promoter region. GA-binding proteins selectively bind at these positions, respectively, causing an activation of the promoter and overexpression of TERT. GABP is a multimeric protein consisting of GABPA and GABPB with its isoforms GABPB1, GABPB1-L, GABPB1-S, GABPB2.

Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.

Background: Low-grade gliomas (LGGs) are known to progress to glioblastoma (GBM), decreasing the chances of survival. The tumor necrosis factor receptor CD40 and its ligand CD40L have shown value as biomarkers for GBM. The present study evaluated the role of CD40/CD40L in LGG and GBM in differentiating isocitrate dehydrogenase (IDH) wild-type and IDH-mutant GBM.

Death Receptor 6 (DR6) Is Overexpressed in Astrocytomas.

Background/aim: Death receptor 6 (DR6) is a member of the tumor necrosis factor receptor superfamily. The expression of DR6 is elevated in different kinds of tumors including ovarian, breast cancer and adult sarcoma. In these tumors, the receptor may be handled as a new diagnostic and prognostic marker.

Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival.

Background/aim: The tumor necrosis factor FAS is overexpressed in high-grade gliomas (HGG). Only little is known about FAS or FAS ligand (FAS-L) in low-grade gliomas (LGG). We explored FAS/FAS-L expression in LGG, focusing on differences in primary and relapsed LGG and on its prognostic value.